Ocuphire Pharma Valuation
| OCUPDelisted Stock | USD 1.13 0.06 5.04% |
Today, the company appears to be fairly valued. Ocuphire Pharma holds a recent Real Value of $1.12 per share. The prevailing price of the company is $1.13. Our model determines the value of Ocuphire Pharma from analyzing the company fundamentals such as Shares Outstanding of 26.2 M, return on equity of -0.36, and Operating Margin of (7.49) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Ocuphire Pharma's price fluctuation is dangerous at this time. Calculation of the real value of Ocuphire Pharma is based on 3 months time horizon. Increasing Ocuphire Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Ocuphire Pharma's intrinsic value may or may not be the same as its current market price of 1.13, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.13 | Real 1.12 | Hype 1.13 | Naive 1.2 |
The intrinsic value of Ocuphire Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Ocuphire Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Ocuphire Pharma helps investors to forecast how Ocuphire stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ocuphire Pharma more accurately as focusing exclusively on Ocuphire Pharma's fundamentals will not take into account other important factors: Ocuphire Pharma Total Value Analysis
Ocuphire Pharma is now anticipated to have valuation of (6.57 M) with market capitalization of 34.84 M, debt of 4.04 M, and cash on hands of 17.15 M. The negative valuation of Ocuphire Pharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Ocuphire Pharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(6.57 M) | 34.84 M | 4.04 M | 17.15 M |
Ocuphire Pharma Investor Information
The company has price-to-book ratio of 0.86. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ocuphire Pharma recorded a loss per share of 0.54. The entity last dividend was issued on the 6th of November 2020. The firm had 1:4 split on the 6th of November 2020. Based on the key measurements obtained from Ocuphire Pharma's financial statements, Ocuphire Pharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Ocuphire Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ocuphire Pharma has an asset utilization ratio of 35.31 percent. This connotes that the Company is making $0.35 for each dollar of assets. An increasing asset utilization means that Ocuphire Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Ocuphire Pharma Ownership Allocation
Ocuphire Pharma owns a total of 26.2 Million outstanding shares. Ocuphire Pharma holds 7.33 pct. of its outstanding shares held by insiders and 10.44 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Ocuphire Pharma Profitability Analysis
The company reported the previous year's revenue of 19.05 M. Net Loss for the year was (9.99 M) with loss before overhead, payroll, taxes, and interest of (14.58 M).About Ocuphire Pharma Valuation
The delisted stock valuation mechanism determines Ocuphire Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Ocuphire Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ocuphire Pharma. We calculate exposure to Ocuphire Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ocuphire Pharma's related companies.Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. Ocuphire Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.
Ocuphire Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Ocuphire Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 21.6 M | |
| Forward Price Earnings | 12.0048 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Ocuphire Stock
If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |